Protein Expression Profiles for IPS Risk Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing and treating idiopathic pneumonia syndrome (IPS) following allogeneic hematopoietic stem cell transplantation are limited, with high mortality rates due to the inability to differentiate between infectious and non-infectious lung injuries, and existing treatments have limited efficacy.
Innovation Solution
The use of protein expression profiles, specifically those of LPS binding protein, Mannose-binding protein-C, PGLYRP2, attractin, and lumican, to characterize the risk and progression of IPS, allowing for the selection of appropriate therapeutic regimens and the administration of TNF-α inhibitors for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum anti-microbial agents are administered for treatment of IPS, then infectious lung injury can be treated, but non-infectious lung injury cannot be differentiated and treated appropriately, leading to high mortality
Solution Approach 1:
The patent introduces protein expression profiles (specifically LBP, MBL2, PGLYRP2, attractin, and lumican) as intermediary biomarkers to differentiate between infectious and non-infectious lung injury. These protein markers serve as mediators that enable clinicians to identify IPS patients who require TNF-α inhibitor treatment rather than just broad-spectrum antibiotics, thereby improving treatment efficacy while reducing unnecessary antimicrobial exposure.
Solution Approach 2:
The patent replaces traditional mechanical diagnostic methods (such as bronchoalveolar lavage and lung biopsy) with a biochemical profiling approach using protein expression analysis. This substitution allows for non-invasive differentiation between infectious and non-infectious causes of lung injury, enabling earlier and more accurate identification of IPS patients for targeted therapy.
2Reliability
If TNF-α inhibitors are administered for treatment of IPS, then patient outcomes may improve, but identification of responsive patients is difficult without robust diagnostic criteria
Solution Approach 1:
The patent performs preliminary characterization of protein expression profiles in patients prior to initiating TNF-α inhibitor therapy. By measuring levels of LBP, MBL2, PGLYRP2, attractin, and lumican before treatment, the system identifies patients at high risk for IPS and those most likely to respond to TNF-α inhibitors, enabling proactive and targeted treatment rather than reactive therapy.
Solution Approach 2:
The patent establishes feedback loops by continuously monitoring protein expression levels during and after treatment. Changes in the expression profiles of the identified proteins provide feedback on treatment response, allowing clinicians to adjust therapy accordingly and identify patients who are responsive to TNF-α inhibitors based on their protein profile dynamics rather than static baseline values.
3Measurement precision
If lung biopsies are performed to differentiate infectious and non-infectious causes, then diagnostic accuracy improves, but the procedure is invasive and time-consuming
Solution Approach 1:
The patent creates a biochemical copy or profile of the lung injury state through measurement of protein expression in readily available samples (such as serum or bronchoalveolar lavage fluid). This protein expression profile serves as a non-invasive surrogate that mirrors the pathological state without requiring actual tissue biopsy, thereby maintaining diagnostic accuracy while eliminating the invasiveness and time requirements of surgical biopsy procedures.
Data Source
AI summary
A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.